All News

“On the basis of these results, (LuPSMA) appears to represent a new class of effective therapy for men with metastatic castration-resistant prostate cancer,” said Dr. Michael S. Hofman.

The Food and Drug Administration approves Nyvepria, the biosimilar to Neulasta, to help treat and prevent infections in patients undergoing myelosuppressive chemotherapy.

A simple banana split can be a powerful memory, and a powerful tool, to help caregivers and patients find the strength to keep going on their cancer journey.

CURE is kicking off its summer recipe series "Cooking With Cure". Through the summer, we'll be highlighting simple and healthy recipes recommended by oncology dieticians from the John Theurer Cancer Center for patients with cancer and survivors. First up, is a fresh pasta dish with sardines, capers and sundried tomatoes.

The Food and Drug Administration approved Opdivo for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based chemotherapy.

The presentation of the complete data from the NRG-GY004 trial comes just months after AstraZeneca and Merck announced in a press release that the combination failed to meet its primary endpoint of progression-free survival.

Living with lymphedema is challenging and summers can be especially difficult, but with a few helpful tips, it can be an enjoyable time.

“These results provide compelling evidence for early darolutamide (Nubeqa) treatment in men with nonmetastatic CRPC,” lead study author Dr. Karim Fizazi, said in a virtual presentation during the meeting.

The allogeneic “off-the-shelf” CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and a manageable safety profile in patients with pretreated large B-cell and follicular lymphomas.

Even those who have undergone mastectomies can enjoy a vintage bralette. And maybe being more comfortable with who I am, a survivor who did not opt for reconstruction, can be a lesson to others.

Join us online for an informative chronic lymphocytic leukemia webinar on Wednesday, June 17, 2020, at 7 - 8 p.m. ET.

After a median follow-up of 15.8 months, patients within the mCRPC cohort who received the combination achieved an objective response rate of 33%.

Oncology dietician Rachel J. Wong, RD, CSO, LD, has a shelf-stable healthy recipe for you to help you make an easy meal when it's hard to get to the grocery store during the pandemic.

To commemorate National Cancer Survivors Day on June 7, CURE® invited its readers to share their encouraging stories of survival.

Getting kidney cancer treatment during the COVID-19 pandemic.

Kidney cancer positives that might come from this pandemic.

How kidney cancer affects the risks of coronavirus.

Cancer patients sometimes require blood due to anemia, blood loss during surgery, or as a result of negative side effects radiation or chemotherapy have on platelet or red blood cell counts.

A message from the KCA’s CEO and President about COVID-19.

Here is a roundup of the latest news and updates for patients with Chronic Lymphocytic Leukemia from CURE.

Kidney cancer changed how Tracie saw her world.

On his motorcycle, Stewy rides for kidney cancer.

A clinical trial and a positive attitude helped Bill Brown ring the bell.

Dawne Gee worked hard to get answers about her kidney cancer.

“These results continue to support pembrolizumab (Keytruda) plus axitinib (Inlyta) as a standard of care for patients with previously untreated advanced RCC,” said lead study author Dr. Elizabeth R. Plimack.

A cancer survivor explains why being in remission feels similar to worrying about getting COVID-19.

From the Food and Drug Administration asking pharmaceutical companies to voluntarily recall metformin, a type 2 diabetes medication, as it contains high levels of the cancer-causing contaminant NDMA to an NHL team’s fanbase showing support to a player as he finishes treatment for Ewing sarcoma, here’s what is making the headlines in the cancer space this week.

Patients participating in phase 1 clinical trials could benefit from the integration of palliative care, according to data presented at the 2020 ASCO Virtual Scientific Meeting.

“The superior efficacy of venetoclax-obinutuzumab has been observed and maintained in the current follow up,” Dr. Othman Al-Sawaf, of University Hospital of Cologne in Germany, said during a pre-recording presentation at the 2020 ASCO Virtual Scientific Program.